Clinical Trials Logo

Advanced Refractory Solid Tumors clinical trials

View clinical trials related to Advanced Refractory Solid Tumors.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04324372 Completed - Clinical trials for Advanced Refractory Solid Tumors

Clinical Study of HEC68498 in Patients With Advanced Refractory Solid Tumors

Start date: February 27, 2019
Phase: Phase 1
Study type: Interventional

Clinical study of HEC68498 in patients with advanced refractory solid tumors. The primary objective is to determine the maximum tolerated dose and dose limiting toxicity of HEC68498 in patients with advanced refractory solid tumors

NCT ID: NCT04200404 Completed - Clinical trials for Advanced Refractory Solid Tumors

A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors

Start date: December 13, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, open-label study of CS1001 in combination with regorafenib in participants with advanced or refractory cancers. There will be a dose escalation portion in "allcomers"to find a suitable dose of regorafenib for combination use with CS1001. This study will also enroll participants with specific tumor types in the phase II part of the study to assess the efficacy, pharmacokinetics and safety of the combined regimen (RP2D of regorafenib + CS 1001)

NCT ID: NCT03349073 Completed - Clinical trials for Advanced Refractory Solid Tumors

An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors

Start date: September 14, 2017
Phase: Phase 1
Study type: Interventional

T-1101 is a novel anti-cancer agent being developed by Taivex Therapeutics Corporation, and is being studied in a phase I dose escalation trial, protocol TAI-001. That trial's primary aim is to study the safety and tolerability of T-1101 (Tosylate) in subjects with advanced refractory solid tumors, and provides for a maximum of 2 cycles of treatment. At the end of 2 cycles of treatment, it is likely that some patients will be continuing to receive clinical benefit from T-1101 (Tosylate). The intention of this program is to enable these patients to continue to receive T-1101 (Tosylate) at the discretion of the principal investigators and Taivex Therapeutics Corporation.